A study on COVID-19 patients in a period from January 2022 to August 2022 in Assiut city

• Published in: Microbes and Infectious Diseases 2024-02, Vol.5 (1), p.11-19
• Main Authors: Esraa Abdelaziz, amany Adawy, Ahmed Hasanein, Hytham Abdalla, Ragaa Rashwan
• Format: Article
• Language: English
• Subjects: comorbidities; covid-19; risk factors
• ISSN: 2682-4132; 2682-4140
• DOI: 10.21608/mid.2023.232236.1601

Background: Coronavirus disease-2019 (COVID-19) mortality rates are increasing globally. Protection is especially important for those who are at risk for serious and fatal disease. Furthermore, factors increasing these risks are of interest in the search of potential treatments. The study's goal is to improve our understanding of how risk factors affect COVID-19 fatality rates. Methods: Data was collected for all 100 COVID- 19 adult patients who admitted to Chest Hospital, Assiut University Hospitals and other quarantine hospitals in Assiut, Egypt with confirmed COVID-19 by RT-PCR from January 2022 to August2022.The patient cohort was classified into severe group (n=32) cases developed as severe symptoms and needed critical care support (ICU). A total of 68 patients did not require intensive care (ICU) and were thus classified as non-severe. Follow-up was completed on October, 2022, at which time all patients either were discharged from the hospital as “cured” or had a fatal outcome of the disease. Results: 56.0% of patients were ≥60 years, 65 patients (65%) were of the male gender. The most prevalent symptoms among patients were dyspnea (98%), cough (93%) followed by fever (74%). The most prevalent comorbidities hypertension (37%), diabetes mellitus (34%), and followed by chronic obstructive pulmonary disease (19%).32.0% of patients with COVID-19 infection admitted ICU, and 18.0% of patients were died. Conclusion: In this study, the most common risk factors associated with COVID-19 among the studied population were age ≥60 years, male gender (65%) and comorbidities (hypertension (37.0%), diabetes mellitus (34.0%) and COPD (19.0%)). Also, age and comorbidities were significantly higher in died patients when compared with cured patients.